Kymera Therapeutic/$KYMR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kymera Therapeutic
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Ticker
$KYMR
Sector
Primary listing
Employees
218
Headquarters
Website
KYMR Metrics
BasicAdvanced
$4.3B
-
-$3.48
2.18
-
Price and volume
Market cap
$4.3B
Beta
2.18
52-week high
$63.96
52-week low
$19.45
Average daily volume
834K
Financial strength
Current ratio
8.32
Quick ratio
8.059
Long term debt to equity
7.416
Total debt to equity
8.823
Interest coverage (TTM)
-996.36%
Profitability
EBITDA (TTM)
-305.056
Gross margin (TTM)
-550.56%
Net profit margin (TTM)
-616.03%
Operating margin (TTM)
-697.51%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-19.92%
Return on equity (TTM)
-33.26%
Valuation
Price to revenue (TTM)
107.15
Price to book
4.39
Price to tangible book (TTM)
4.39
Price to free cash flow (TTM)
-18.942
Free cash flow yield (TTM)
-5.28%
Free cash flow per share (TTM)
-3.192
Growth
Revenue change (TTM)
-49.51%
Earnings per share change (TTM)
43.55%
3-year revenue growth (CAGR)
-7.64%
3-year earnings per share growth (CAGR)
8.62%
What the Analysts think about KYMR
Analyst ratings (Buy, Hold, Sell) for Kymera Therapeutic stock.
Bulls say / Bears say
Gilead Sciences has signed an option and license agreement with Kymera worth up to $750 million—including an $85 million upfront payment—to develop Kymera’s molecular glue oncology programs, delivering significant funding that does not dilute ownership and providing strong validation of Kymera’s technology platform.
Kymera’s KT-621 STAT6 degrader showed a good safety profile and led to complete or near-complete STAT6 degradation in both blood and skin at all dose levels in its Phase 1 healthy volunteer study. This result triggered a nearly 50 percent jump in Kymera’s share price and supports the promise of its oral protein degradation approach.
Kymera’s partnership with Sanofi is set to bring its next-generation IRAK4 degrader KT-485 into clinical trials by the end of the year, with the possibility of up to $975 million in milestone payments. This highlights the robustness and diversity of Kymera’s immunology pipeline.
Leerink Partners analyst Faisal Khurshid stated that although Phase 1 STAT6 degradation results confirm target engagement, there is still uncertainty about how relevant STAT6 depletion will be for patients and what therapeutic benefits it will actually deliver.
Kymera faces competition in the STAT6 degrader field since Sanofi has just opted to license a competing STAT6 degrader from Nurix Therapeutics, which could fragment both the market and the attention of potential partners.
Despite the headline figure of a potential $750 million deal, Gilead is only paying $85 million upfront, with most of the value tied to future milestones and royalties, exposing Kymera to long development timelines and uncertainty around near-term revenue.
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
KYMR Financial Performance
Revenues and expenses
KYMR Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kymera Therapeutic stock?
Kymera Therapeutic (KYMR) has a market cap of $4.3B as of October 17, 2025.
What is the P/E ratio for Kymera Therapeutic stock?
The price to earnings (P/E) ratio for Kymera Therapeutic (KYMR) stock is 0 as of October 17, 2025.
Does Kymera Therapeutic stock pay dividends?
No, Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders as of October 17, 2025.
When is the next Kymera Therapeutic dividend payment date?
Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Kymera Therapeutic?
Kymera Therapeutic (KYMR) has a beta rating of 2.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.